Pfizer Inc (PFE) 34.74 $PFE
Watch for Shares of Pfizer (PFE) to Approach Support at $34.86
Comtex SmarTrend(R) - Mon Jun 13, 9:05AM CDT
Shares of Pfizer (NYSE
FE) opened today below their pivot of $35.23 and have already reached the first level of support at $35.08. Investors may be interested in a cross of the next downside pivot targets of $34.86 and $34.49.
PFE: 34.74 (-0.55)
Agios Reports Favorable Phase II PK Deficiency Study Data
Zacks Equity Research - Zacks Investment Research - Mon Jun 13, 8:56AM CDT
Agios Pharmaceuticals (AGIO) reported encouraging initial data from an ongoing phase II DRIVE-PK study on pyruvate kinase deficiency candidate AG-348.
PFE: 34.74 (-0.55), RTRX: 17.19 (-0.21), AGIO: 51.97 (+1.62), BMY: 72.22 (-0.43)
Bull of the Day: Pfizer (PFE)
Neena Mishra - Zacks Investment Research - Mon Jun 13, 8:53AM CDT
Bull of the Day: Pfizer (PFE)
PFE: 34.74 (-0.55)
Pfizer, New York & Company, Wal-Mart Stores, Amazon and Alibaba Home highlighted as Zacks Bull and Bear of the Day
Zacks Equity Research - Zacks Investment Research - Mon Jun 13, 8:30AM CDT
Pfizer, New York & Company, Wal-Mart Stores, Amazon and Alibaba Home highlighted as Zacks Bull and Bear of the Day
AMZN: 715.24 (-2.67), NWY: 1.38 (-0.06), PFE: 34.74 (-0.55), WMT: 70.53 (-0.61), BABA: 75.45 (-0.47)
Pfizer Reveals Final Phase III Data on Inotuzumab Ozogamicin
Zacks Equity Research - Zacks Investment Research - Mon Jun 13, 7:50AM CDT
Pfizer (PFE) announced final data from the phase III study on inotuzumab ozogamicin for the treatment of relapsed/refractory acute lymphoblastic leukemia.
ANIP: 53.19 (+1.14), MRK: 56.11 (-0.70), PFE: 34.74 (-0.55), BMY: 72.22 (-0.43)
Spark Therapeutics Announces Updated Data from First Cohort in Hemophilia B Phase 1/2 Trial Demonstrating Consistent, Sustained Therapeutic Levels of Factor IX Activity
GlobeNewswire - Mon Jun 13, 6:15AM CDT
All four subjects received one-time administration of SPK-9001 at initial low dose for a cumulative 58-weeks of follow-up without the need for immunosuppression
ONCE: 52.55 (-1.03), PFE: 34.74 (-0.55)
Merck and Pfizer Announce Two Pivotal Phase 3 Studies for Ertugliflozin, an Investigational SGLT-2 Inhibitor, Met Primary Endpoints, Showing Significant A1C Reductions in Patients with Type 2 Diabetes
BusinessWire - Sat Jun 11, 10:00AM CDT
Merck (NYSE:MRK), known as MSD outside the United States and Canada, in partnership with Pfizer Inc. (NYSEFE), today announced that two Phase 3 studies (VERTIS Mono and VERTIS Factorial) of ertugliflozin, an investigational oral SGLT-2 inhibitor for the treatment of patients with type 2 diabetes, met their primary endpoints. The study results showed statistically significant reductions in A1C (a measure of average blood glucose) for both ertugliflozin doses tested (5 mg and 15 mg daily). These results from the VERTIS clinical development program of ertugliflozin will be presented for the first time at the 76th Scientific Sessions of the American Diabetes Association, which are being held in New Orleans from June 10-14, 2016.
PFE: 34.74 (-0.55), MRK: 56.11 (-0.70)
ViiV Healthcare Announces FDA Approval to Lower the Weight Limit for dolutegravir in Children and Adolescents Living With HIV
PR Newswire Europe - Fri Jun 10, 8:18AM CDT
LONDON, June 10, 2016 /PRNewswire/ --
PFE: 34.74 (-0.55), GSK: 40.83 (-0.10)
Merck (MRK) to Acquire Afferent in Deal Worth Up To $1.25B
Arpita Dutt - Zacks Investment Research - Fri Jun 10, 7:53AM CDT
Merck's (MRK) upcoming acquisition of biotech company Afferent will add a mid-stage chronic cough candidate to its pipeline.
JNJ: 116.79 (-0.22), MRK: 56.11 (-0.70), PFE: 34.74 (-0.55), BMY: 72.22 (-0.43)
ICON Announces Service Agreement with Pfizer
BusinessWire - Fri Jun 10, 5:00AM CDT
ICON plc, (NASDAQ: ICLR), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced it has signed a three-year agreement with Pfizer Inc. (NYSEFE). Under the terms of the agreement, Pfizer has the right to extend the term for up to an additional two years. Financial details of the agreement were not disclosed.
PFE: 34.74 (-0.55), ICLR: 66.18 (-1.36)
Novartis (NVS) Announces Positive Results on Migraine Drug
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 5:22PM CDT
Novartis AG (NVS) reported positive first results from the global phase II study, 20120295 on pipeline candidate, AMG 334 (erenumab).
PFE: 34.74 (-0.55), AMGN: 153.08 (-1.70), BMY: 72.22 (-0.43), NVS: 77.33 (-1.61)
Theravance Biopharma Signs Licensing Deal with Takeda
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 10:23AM CDT
Theravance Biopharma (TBPH) has entered into a global license, development and commercialization agreement with Takeda (TKPYY) for TD-8954.
PFE: 34.74 (-0.55), TBPH: 22.35 (-0.33), BMY: 72.22 (-0.43)
7 Medical Stocks to Buy with Market-Beating Yields
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 8:50AM CDT
Medical is one of the very few sectors that generally show great resilience during volatile phases in the market.
KND: 11.07 (-0.45), ABT: 37.86 (-0.54), JNJ: 116.79 (-0.22), PFE: 34.74 (-0.55), BMY: 72.22 (-0.43), HLS: 40.28 (-0.26), DRAD: 5.50 (+0.01)
Pro Golfer Jim Furyk Teams Up With Pfizer To Raise Awareness For Pneumococcal Pneumonia And The Importance Of Older Adult Vaccination
BusinessWire - Thu Jun 09, 6:30AM CDT
This Father's Day, Jim Furyk will be thinking about more than just strategizing for the next Major as he joins Pfizer to encourage adults 65 and older to take responsibility for their health. On Father's Day 2003, Furyk won a Major with his coach and father, Mike, by his side.(1) This year, Jim will be one of 156 golfers to gather in Oakmont, PA, to play in one of professional golf's major championship tournaments.
PFE: 34.74 (-0.55)
Innovus Pharma (INNV)'s Vesele Could Be the Best Complementary Product for Viagra and Cialis's $3.2 Billion Dollar Erectile Dysfunction Market
Marketwire Canada - Thu Jun 09, 5:00AM CDT
SAN DIEGO, CA--(Marketwired - Jun 9, 2016) - Innovus Pharma (OTCQB: INNV) -- The global erectile dysfunction drug market is expected to reach $3.2 billion USD by 2022 according to a new report by Grand View Research Inc. Male sexual dysfunction has become a multi-billion-dollar market fueled by sales of erectile dysfunction drugs like Viagra and Cialis. In fact, Pfizer Inc.'s Viagra surpassed $1 billion in sales during its first year despite having lower than usual third-party coverage. The drug has consistently surpassed $1 billion per year in sales since its launch and even briefly reached above the $2 billion mark back in 2012 despite growing competition.
PFE: 34.74 (-0.55)
Pfizer Announces FDA Advisory Committees' Recommend ALO-02 (oxycodone hydrochloride and naltrexone hydrochloride) Extended-Release Capsules for Approval
BusinessWire - Wed Jun 08, 6:15PM CDT
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee voted (9 to 6) in favor of approval of ALO-02 (oxycodone hydrochloride and naltrexone hydrochloride) extended-release capsules for its proposed indication, "management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate."
PFE: 34.74 (-0.55)
After Yesterday's Rally of 1.29% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Wed Jun 08, 12:07PM CDT
Pfizer (NYSEFE) traded in a range yesterday that spanned from a low of $34.67 to a high of $35.33. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $34.99 on volume of 10.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
PFE: 34.74 (-0.55)
Watch for Shares of Pfizer (PFE) to Approach Support at $34.86
Comtex SmarTrend(R) - Mon Jun 13, 9:05AM CDT
Shares of Pfizer (NYSE
FE) opened today below their pivot of $35.23 and have already reached the first level of support at $35.08. Investors may be interested in a cross of the next downside pivot targets of $34.86 and $34.49. PFE: 34.74 (-0.55)
Agios Reports Favorable Phase II PK Deficiency Study Data
Zacks Equity Research - Zacks Investment Research - Mon Jun 13, 8:56AM CDT
Agios Pharmaceuticals (AGIO) reported encouraging initial data from an ongoing phase II DRIVE-PK study on pyruvate kinase deficiency candidate AG-348.
PFE: 34.74 (-0.55), RTRX: 17.19 (-0.21), AGIO: 51.97 (+1.62), BMY: 72.22 (-0.43)
Bull of the Day: Pfizer (PFE)
Neena Mishra - Zacks Investment Research - Mon Jun 13, 8:53AM CDT
Bull of the Day: Pfizer (PFE)
PFE: 34.74 (-0.55)
Pfizer, New York & Company, Wal-Mart Stores, Amazon and Alibaba Home highlighted as Zacks Bull and Bear of the Day
Zacks Equity Research - Zacks Investment Research - Mon Jun 13, 8:30AM CDT
Pfizer, New York & Company, Wal-Mart Stores, Amazon and Alibaba Home highlighted as Zacks Bull and Bear of the Day
AMZN: 715.24 (-2.67), NWY: 1.38 (-0.06), PFE: 34.74 (-0.55), WMT: 70.53 (-0.61), BABA: 75.45 (-0.47)
Pfizer Reveals Final Phase III Data on Inotuzumab Ozogamicin
Zacks Equity Research - Zacks Investment Research - Mon Jun 13, 7:50AM CDT
Pfizer (PFE) announced final data from the phase III study on inotuzumab ozogamicin for the treatment of relapsed/refractory acute lymphoblastic leukemia.
ANIP: 53.19 (+1.14), MRK: 56.11 (-0.70), PFE: 34.74 (-0.55), BMY: 72.22 (-0.43)
Spark Therapeutics Announces Updated Data from First Cohort in Hemophilia B Phase 1/2 Trial Demonstrating Consistent, Sustained Therapeutic Levels of Factor IX Activity
GlobeNewswire - Mon Jun 13, 6:15AM CDT
All four subjects received one-time administration of SPK-9001 at initial low dose for a cumulative 58-weeks of follow-up without the need for immunosuppression
ONCE: 52.55 (-1.03), PFE: 34.74 (-0.55)
Merck and Pfizer Announce Two Pivotal Phase 3 Studies for Ertugliflozin, an Investigational SGLT-2 Inhibitor, Met Primary Endpoints, Showing Significant A1C Reductions in Patients with Type 2 Diabetes
BusinessWire - Sat Jun 11, 10:00AM CDT
Merck (NYSE:MRK), known as MSD outside the United States and Canada, in partnership with Pfizer Inc. (NYSE
FE), today announced that two Phase 3 studies (VERTIS Mono and VERTIS Factorial) of ertugliflozin, an investigational oral SGLT-2 inhibitor for the treatment of patients with type 2 diabetes, met their primary endpoints. The study results showed statistically significant reductions in A1C (a measure of average blood glucose) for both ertugliflozin doses tested (5 mg and 15 mg daily). These results from the VERTIS clinical development program of ertugliflozin will be presented for the first time at the 76th Scientific Sessions of the American Diabetes Association, which are being held in New Orleans from June 10-14, 2016. PFE: 34.74 (-0.55), MRK: 56.11 (-0.70)
ViiV Healthcare Announces FDA Approval to Lower the Weight Limit for dolutegravir in Children and Adolescents Living With HIV
PR Newswire Europe - Fri Jun 10, 8:18AM CDT
LONDON, June 10, 2016 /PRNewswire/ --
PFE: 34.74 (-0.55), GSK: 40.83 (-0.10)
Merck (MRK) to Acquire Afferent in Deal Worth Up To $1.25B
Arpita Dutt - Zacks Investment Research - Fri Jun 10, 7:53AM CDT
Merck's (MRK) upcoming acquisition of biotech company Afferent will add a mid-stage chronic cough candidate to its pipeline.
JNJ: 116.79 (-0.22), MRK: 56.11 (-0.70), PFE: 34.74 (-0.55), BMY: 72.22 (-0.43)
ICON Announces Service Agreement with Pfizer
BusinessWire - Fri Jun 10, 5:00AM CDT
ICON plc, (NASDAQ: ICLR), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced it has signed a three-year agreement with Pfizer Inc. (NYSE
FE). Under the terms of the agreement, Pfizer has the right to extend the term for up to an additional two years. Financial details of the agreement were not disclosed. PFE: 34.74 (-0.55), ICLR: 66.18 (-1.36)
Novartis (NVS) Announces Positive Results on Migraine Drug
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 5:22PM CDT
Novartis AG (NVS) reported positive first results from the global phase II study, 20120295 on pipeline candidate, AMG 334 (erenumab).
PFE: 34.74 (-0.55), AMGN: 153.08 (-1.70), BMY: 72.22 (-0.43), NVS: 77.33 (-1.61)
Theravance Biopharma Signs Licensing Deal with Takeda
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 10:23AM CDT
Theravance Biopharma (TBPH) has entered into a global license, development and commercialization agreement with Takeda (TKPYY) for TD-8954.
PFE: 34.74 (-0.55), TBPH: 22.35 (-0.33), BMY: 72.22 (-0.43)
7 Medical Stocks to Buy with Market-Beating Yields
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 8:50AM CDT
Medical is one of the very few sectors that generally show great resilience during volatile phases in the market.
KND: 11.07 (-0.45), ABT: 37.86 (-0.54), JNJ: 116.79 (-0.22), PFE: 34.74 (-0.55), BMY: 72.22 (-0.43), HLS: 40.28 (-0.26), DRAD: 5.50 (+0.01)
Pro Golfer Jim Furyk Teams Up With Pfizer To Raise Awareness For Pneumococcal Pneumonia And The Importance Of Older Adult Vaccination
BusinessWire - Thu Jun 09, 6:30AM CDT
This Father's Day, Jim Furyk will be thinking about more than just strategizing for the next Major as he joins Pfizer to encourage adults 65 and older to take responsibility for their health. On Father's Day 2003, Furyk won a Major with his coach and father, Mike, by his side.(1) This year, Jim will be one of 156 golfers to gather in Oakmont, PA, to play in one of professional golf's major championship tournaments.
PFE: 34.74 (-0.55)
Innovus Pharma (INNV)'s Vesele Could Be the Best Complementary Product for Viagra and Cialis's $3.2 Billion Dollar Erectile Dysfunction Market
Marketwire Canada - Thu Jun 09, 5:00AM CDT
SAN DIEGO, CA--(Marketwired - Jun 9, 2016) - Innovus Pharma (OTCQB: INNV) -- The global erectile dysfunction drug market is expected to reach $3.2 billion USD by 2022 according to a new report by Grand View Research Inc. Male sexual dysfunction has become a multi-billion-dollar market fueled by sales of erectile dysfunction drugs like Viagra and Cialis. In fact, Pfizer Inc.'s Viagra surpassed $1 billion in sales during its first year despite having lower than usual third-party coverage. The drug has consistently surpassed $1 billion per year in sales since its launch and even briefly reached above the $2 billion mark back in 2012 despite growing competition.
PFE: 34.74 (-0.55)
Pfizer Announces FDA Advisory Committees' Recommend ALO-02 (oxycodone hydrochloride and naltrexone hydrochloride) Extended-Release Capsules for Approval
BusinessWire - Wed Jun 08, 6:15PM CDT
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee voted (9 to 6) in favor of approval of ALO-02 (oxycodone hydrochloride and naltrexone hydrochloride) extended-release capsules for its proposed indication, "management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate."
PFE: 34.74 (-0.55)
After Yesterday's Rally of 1.29% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Wed Jun 08, 12:07PM CDT
Pfizer (NYSE
FE) traded in a range yesterday that spanned from a low of $34.67 to a high of $35.33. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $34.99 on volume of 10.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious. PFE: 34.74 (-0.55)
